Royalty Pharma to Present at Upcoming Investor Conferences
May 07, 2021 09:00 ET
|
RP Management, LLC
NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: Bank of...
Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021
April 21, 2021 16:15 ET
|
RP Management, LLC
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 before the U.S....
Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes
April 21, 2021 08:10 ET
|
RP Management, LLC
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration with MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and...
Royalty Pharma Declares Second-Quarter 2021 Dividend
April 15, 2021 09:00 ET
|
RP Management, LLC
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of $0.17 per class A...
Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
April 08, 2021 07:40 ET
|
RP Management, LLC
Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc...
Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
April 01, 2021 07:30 ET
|
RP Management, LLC
NEW YORK, April 01, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from...
Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director
March 30, 2021 08:00 ET
|
RP Management, LLC
NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- The Board of Directors of Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Henry...
Royalty Pharma Reports Q4 2020 and Full-Year Results
February 17, 2021 07:00 ET
|
RP Management, LLC
Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Flow(2)$2.4 billion of acquisitions announced in 2020; maintained leading share of biopharma royalty funding...
Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021
January 22, 2021 08:00 ET
|
RP Management, LLC
NEW YORK, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter 2020 financial results on Wednesday, February 17, 2021 before the...
Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences
January 19, 2021 08:30 ET
|
RP Management, LLC
NEW YORK and WALTHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire...